X4 Pharmaceuticals Inc (NAS:XFOR)
$ 1.08 0 (0%) Market Cap: 181.37 Mil Enterprise Value: 158.78 Mil PE Ratio: 0 PB Ratio: 108.00 GF Score: 35/100

X4 Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 02:00PM GMT
Release Date Price: $5.29 (+1.93%)
Emma Nealon
Cantor Fitzgerald - Analyst

Good morning, everyone, and thank you for joining us on day four of the virtual Cantor Healthcare Conference. My name is Emma Nealon, and I am one of the small/mid-cap biotech analysts here Cantor. It is my pleasure to be hosting X4 Therapeutics this morning for a fireside chat. And joining us today from X4 is CEO, Paula Ragan.

So let's start with a brief overview of X4 and your lead asset, mavorixafor. Where did the asset come from? And maybe walk us through the mechanism of action.

Paula Ragan
X4 Pharmaceuticals, Inc. - President and CEO

Sure. Good morning, Emma, and thanks so much for hosting us at the Cantor conference. We appreciate it. So you know we are really excited about our lead asset, mavorixafor. It is a drug that impacts and modulates the immune system, which you can appreciate has tremendous potential as we think about it here, and certainly in the last year and a half that we've all lived through. In terms of what CXCR4 -- the target -- it does in the healthy state is it helps regulate the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot